Chardan Capital Estimates MeiraGTx FY2026 Earnings

MeiraGTx Holdings plc (NASDAQ:MGTX) – Research analysts at Chardan Capital issued their FY2026 earnings per share (EPS) estimates for MeiraGTx in a research note issued to investors on Monday, March 24th. Chardan Capital analyst D. Gataulin expects that the company will earn ($1.09) per share for the year. Chardan Capital currently has a “Buy” rating and a $36.00 target price on the stock. The consensus estimate for MeiraGTx’s current full-year earnings is ($1.48) per share.

Separately, Royal Bank of Canada boosted their price objective on MeiraGTx from $11.00 to $13.00 and gave the stock an “outperform” rating in a research note on Monday, March 17th.

MeiraGTx Stock Performance

MGTX opened at $7.23 on Thursday. The stock has a market capitalization of $570.12 million, a price-to-earnings ratio of -5.98, a PEG ratio of 0.37 and a beta of 1.23. MeiraGTx has a fifty-two week low of $3.85 and a fifty-two week high of $8.75. The company has a debt-to-equity ratio of 0.86, a quick ratio of 2.34 and a current ratio of 2.34. The company has a fifty day moving average of $6.78 and a 200 day moving average of $6.02.

MeiraGTx (NASDAQ:MGTX) last posted its quarterly earnings results on Thursday, March 13th. The company reported ($0.50) earnings per share for the quarter, missing the consensus estimate of ($0.48) by ($0.02). The business had revenue of $21.39 million during the quarter, compared to the consensus estimate of $1.50 million. MeiraGTx had a negative return on equity of 146.38% and a negative net margin of 633.05%.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Summit Investment Advisors Inc. raised its holdings in shares of MeiraGTx by 106.7% in the 4th quarter. Summit Investment Advisors Inc. now owns 4,871 shares of the company’s stock valued at $30,000 after purchasing an additional 2,515 shares in the last quarter. Tower Research Capital LLC TRC increased its holdings in MeiraGTx by 68.1% during the fourth quarter. Tower Research Capital LLC TRC now owns 4,975 shares of the company’s stock valued at $30,000 after buying an additional 2,016 shares during the period. BNP Paribas Financial Markets raised its stake in MeiraGTx by 142.5% in the third quarter. BNP Paribas Financial Markets now owns 9,319 shares of the company’s stock worth $39,000 after buying an additional 5,476 shares in the last quarter. Polymer Capital Management US LLC purchased a new stake in MeiraGTx during the fourth quarter worth $88,000. Finally, China Universal Asset Management Co. Ltd. boosted its position in MeiraGTx by 11.3% during the 4th quarter. China Universal Asset Management Co. Ltd. now owns 16,571 shares of the company’s stock valued at $101,000 after acquiring an additional 1,685 shares in the last quarter. 67.48% of the stock is currently owned by institutional investors.

Insider Buying and Selling

In related news, CEO Alexandria Forbes sold 35,839 shares of MeiraGTx stock in a transaction dated Tuesday, January 7th. The shares were sold at an average price of $6.47, for a total transaction of $231,878.33. Following the completion of the sale, the chief executive officer now owns 1,395,102 shares in the company, valued at $9,026,309.94. This trade represents a 2.50 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, CFO Richard Giroux sold 24,000 shares of the business’s stock in a transaction that occurred on Tuesday, January 21st. The shares were sold at an average price of $6.29, for a total value of $150,960.00. Following the completion of the sale, the chief financial officer now owns 849,947 shares of the company’s stock, valued at $5,346,166.63. The trade was a 2.75 % decrease in their position. The disclosure for this sale can be found here. 8.40% of the stock is owned by corporate insiders.

MeiraGTx Company Profile

MeiraGTx Holdings plc, a clinical stage gene therapy company, focusing on developing treatments for patients with serious diseases. The company develops various therapies for ocular diseases, including inherited retinal diseases and large degenerative ocular diseases, neurodegenerative diseases, and xerostomia.